Lansoprazole Sodium, a sodium salt form of Lansoprazole, is an orally active inhibitor of proton pump, preventing the stomach from producing acid. Lansoprazole enhances the expression and transcriptional effectiveness of runt-related transcription factor 2 (Runx2), stimulating osteoprogenitor cell’s commitment and differentiation toward their lineage.

Lefamulin (BC-3781), is a pleuromutilin antibiotic, inhibits protein synthesis by binding to the peptidyl transferase center of the 50S bacterial ribosome. It is effective against a range of gram-positive pathogens involved in community-acquired bacterial pneumonia (CABP), including Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, Legionella pneumophila, Chlamydophila pneumoniae, Staphylococcus aureus (including methicillin-resistant and vancomycin-intermediate strains), and […]

Lefamulin (BC-3781), is a pleuromutilin antibiotic, inhibits protein synthesis by binding to the peptidyl transferase center of the 50S bacterial ribosome. It is effective against a range of gram-positive pathogens involved in community-acquired bacterial pneumonia (CABP), including Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, Legionella pneumophila, Chlamydophila pneumoniae, Staphylococcus aureus (including methicillin-resistant and vancomycin-intermediate strains), and […]

Lefamulin (BC-3781), is a pleuromutilin antibiotic, inhibits protein synthesis by binding to the peptidyl transferase center of the 50S bacterial ribosome. It is effective against a range of gram-positive pathogens involved in community-acquired bacterial pneumonia (CABP), including Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, Legionella pneumophila, Chlamydophila pneumoniae, Staphylococcus aureus (including methicillin-resistant and vancomycin-intermediate strains), and […]

Lisinopril(MK-521) is a potent inhibitor of angiotensin-1 converting enzyme (sACE-1) with an IC50 of 1.9 nM. It demonstrates significant efficacy in the management of hypertension and heart failure, potentially improving cardiovascular outcomes.

Lisinopril(MK-521) is a potent inhibitor of angiotensin-1 converting enzyme (sACE-1) with an IC50 of 1.9 nM. It demonstrates significant efficacy in the management of hypertension and heart failure, potentially improving cardiovascular outcomes.

Lefamulin (BC-3781), is a pleuromutilin antibiotic, inhibits protein synthesis by binding to the peptidyl transferase center of the 50S bacterial ribosome. It is effective against a range of gram-positive pathogens involved in community-acquired bacterial pneumonia (CABP), including Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, Legionella pneumophila, Chlamydophila pneumoniae, Staphylococcus aureus (including methicillin-resistant and vancomycin-intermediate strains), and […]

Lodoxamide (U-42585E free acid) is a potent agonist of GPR35 with an EC50 of 1 nM. It also inhibits eosinophil peroxidase release after IgA activation and reduces eosinophil cationic protein and eosinophil-derived neurotoxin, suggesting direct effects on eosinophils. It is a mast cell stabilizer used to treat asthma, allergic conjunctivitis, and superior limbic keratoconjunctivitis.

Lodoxamide (U-42585E free acid) is a potent agonist of GPR35 with an EC50 of 1 nM. It also inhibits eosinophil peroxidase release after IgA activation and reduces eosinophil cationic protein and eosinophil-derived neurotoxin, suggesting direct effects on eosinophils. It is a mast cell stabilizer used to treat asthma, allergic conjunctivitis, and superior limbic keratoconjunctivitis.

Lodoxamide (U-42585E free acid) is a potent agonist of GPR35 with an EC50 of 1 nM. It also inhibits eosinophil peroxidase release after IgA activation and reduces eosinophil cationic protein and eosinophil-derived neurotoxin, suggesting direct effects on eosinophils. It is a mast cell stabilizer used to treat asthma, allergic conjunctivitis, and superior limbic keratoconjunctivitis.